<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1512246416
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL-LIPURO1% INJ OR INF AMPOULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="B. BRAUN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 971]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Medical Supplies And Services Co Ltd (Mediserv)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Propofol-Lipuro 10 mg/ml belongs to a group of medicines called general<br />anaesthetics. General anaesthetics are used to cause unconsciousness<br />(sleep) so that surgical operations or other procedures can be performed.<br />They can also be used to sedate you (so that you are sleepy but not completely<br />asleep).<br />Propofol-Lipuro 10 mg/ml will be given to you as an injection by a doctor.<br />In adults and children over 1 month of age Propofol Lipuro 10 mg/ml is<br />used to:<br />&bull; Help put you to sleep before an operation or other procedure<br />&bull; Keep you asleep during an operation or other procedure.<br />&bull; Sedate you during diagnostic and surgical procedures, alone or in combination<br />with local or regional anaesthesia.<br />In people over 16 years of age it is also used to:<br />&bull; Sedate you when receiving artificial respiration in an Intensive Care Unit<br />(ICU).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Propofol-Lipuro 10 mg/ml:<br />&bull; if you are allergic to propofol, soya, peanut or any of the other ingredients<br />of this medicine (listed in section 6).<br />&bull; if you are 16 years of age or younger for sedation during intensive care.<br />If any of the above apply to you, do not have Propofol-Lipuro<br />10 mg/ml and tell your doctor, anaesthetist or nurse. If you are not sure,<br />talk to one of these people before having Propofol-Lipuro 10 mg/ml.</p><p>Warnings and precautions<br />The use of Propofol 10 mg/ml is not recommended in newborn infants<br />Talk to your doctor, anaesthetist or nurse before using Propofol-Lipuro<br />10 mg/ml</p><p>Before you have this medicine, tell your doctor, anaesthetist or nurse<br />&bull; if you have ever been told that you have very high levels of fat in your<br />blood,<br />&bull; if you have ever been told that your body has problems using fat,<br />&bull; if your body has lost lots of water (you are dehydrated),<br />&bull; if your blood volume is too low (hypovolaemia),<br />&bull; if you are very weak (debilitated) or have heart, kidney or liver problems,<br />&bull; if you have high pressure within in the skull,<br />&bull; if you have problems with your breathing,<br />&bull; if you have ever had a fit or convulsion,<br />&bull; if you have been generally unwell for some time,<br />&bull; if your body has lost lots of water (you are dehydrated),<br />&bull; if you have mitochondrial disease.</p><p>Please tell your doctor if you have one of these diseases or conditions.<br />If you are receiving other lipids by a drip into your vein at the same time<br />your doctor will pay attention to your total daily fat intake.<br />Propofol will be administered to you by a physician trained in anaesthesia<br />or intensive care. You will be constantly monitored during anaesthesia and<br />waking-up time.<br />If you experience signs of the so called &lsquo;propofol infusion syndrome&rsquo; (for a<br />detailed list of the symptoms see section 4 &lsquo;Possible side effects&rsquo;, a doctor<br />must be called if the following happens&rsquo;) your doctor will immediately stop<br />the dosage of propofol.</p><p>Studies in young animals and suggest that repeated or lengthy use of general<br />anaesthetics or sedation drugs in children younger than 3 years or in<br />pregnant women during their third trimester may have negative effects<br />on the development of the child&rsquo;s brain. The clinical significance of these<br />nonclinical findings is not known.<br />Please see also section &lsquo;Driving and using machines&rsquo; for precautions to be<br />taken after the use of propfol.</p><p>Children and adolescents<br />The use of Propofol-Lipuro is not recommended in newborn infants.</p><p>This medicine must not be used in patients of 16 years of age or younger for<br />sedation for intensive care (see section &lsquo;Do not use Propofol-Lipuro 10 mg/<br />ml&rsquo;).</p><p>Other medicines and Propofol-Lipuro 10 mg/ml<br />Tell your doctor or pharmacist if you are taking or have recently taken or<br />might take any other medicines.<br />This includes medicines that you buy without a prescription and herbal<br />medicines.<br />Propofol has effectively been used with different regional anaesthesia<br />techniques that only numb a part of your body (epidural and spinal anaesthesia).</p><p>Additionally, safe use has been demonstrated in combination with<br />&bull; drugs you receive before surgery<br />&bull; other medicines like muscle relaxing drugs<br />&bull; anaesthetic drugs that can be inhaled<br />&bull; pain killers.<br />However your physician may give you lower doses of propofol if general<br />anaesthesia or sedation is needed as a supplement to regional anaesthesia<br />techniques.<br />Your doctor will consider that other medicines with an inhibiting effect on<br />the central nervous system may increase the effects of propofol when given<br />together with propofol.<br />Special care will also be taken if you receive in parallel an antibiotic containing<br />rifampicin &ndash; you may develop profound low blood pressure.<br />Your dosage might be reduced by your doctor if you are also treated with<br />valproate (anticonvulsant).<br />Propofol-Lipuro 10 mg/ml with alcohol<br />Your doctor will advise you on the consumption of alcohol before and after<br />the use of Propofol-Lipuro.<br />Pregnancy and breast-feeding<br />Do not have Propofol if you are pregnant unless absolutely necessary.<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />Propofol-Lipuro should not be used during pregnancy unless it is definitely<br />needed. It crosses the placenta and may depress the vital functions of the<br />newborn.<br />However, propofol may be used during an induced abortion.<br />If you are breast-feeding your child you should stop nursing and discard<br />breast milk for 24 hours after you have received Propofol-Lipuro 10 mg/ml.<br />Studies in breast-feeding women showed that propofol is excreted in small<br />amounts into the milk.</p><p><strong>Driving and using machines</strong><br />After having Propofol-Lipuro 10 mg/ml, you may still feel sleepy for some<br />time. Do not drive or use any tools or machines until you are sure the effects<br />have worn off.<br />Your doctor will advise you<br />&bull; if you should be accompanied when you are leaving.<br />&bull; when you can drive and use machinery again.<br />&bull; on the use of other tranquillizing drugs (e.g. tranquillizers, strong pain<br />killers, alcohol).<br />Propofol-Lipuro 10 mg/ml contains sodium and soya-bean oil<br />This medicine contains less than 1 mmol sodium (23 mg) in 100 ml, that is,<br />to say essentially &lsquo;sodium free&rsquo;.<br />Propofol-Lipuro contains soya oil. If you are allergic to peanut or soya, do<br />not use this medicinal product</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Propofol-Lipuro 10 mg/ml will only be given by anaesthetists or by specially<br />trained doctors in an intensive care unit.<br />Dosage<br />The dose you are given will vary depending on your age, body weight and<br />physical condition. The doctor will give the correct dose to start and to sustain<br />anaesthesia or to achieve the required level of sedation, by carefully<br />watching your responses and vital signs (pulse, blood pressure, breathing,<br />etc).<br />The doctor will also observe limits of the time of application, if necessary.<br />Propofol-Lipuro 10 mg/ml will usually be given by injection when used to<br />induce general anaesthesia and by continuous infusion (a slower, longer<br />injection) when used to maintain general anaesthesia. It may be given as an<br />infusion either diluted or undiluted. When used as a sedative it will usually<br />be given by infusion.<br />Propofol-Lipuro 10 mg/ml will only be given for a maximum of 7 days.<br />You may need several different medicines to keep you asleep or sleepy,<br />free from pain, breathing in a healthy way and to keep your blood pressure<br />steady. The doctor will decide which medicines you need and when you<br />need them.<br />Method of administration<br />You will receive Propofol-Lipuro 10 mg/ml by intravenous injection or infusion,<br />that is, through a needle or small tube placed in one of your veins.<br />This is usually in the back of your hand or in your forearm.<br />The doctor can also use an electric pump to control how fast the injection<br />is given. This may be done if you are having a long operation or if you are<br />in an Intensive Care Unit.<br />Because Propofol-Lipuro 10 mg/ml does not contain preservatives, an infusion<br />from one vial of Propofol-Lipuro 10 mg/ml will not last longer than 12<br />hours. An infusion from one container of diluted Propofol-Lipuro 10 mg/ml<br />will not last longer than 6 hours.<br />Your circulation and breathing will be constantly monitored while you are<br />being given the injection or infusion.<br />If you received more Propofol-Lipuro 10 mg/ml than you should<br />It is unlikely that this occurs because the doses you receive are very carefully controlled.</p><p>&nbsp;Yet if you accidentally got an overdose, this could lead to depression of<br />heart function and breathing. In this case your doctor will employ any necessary<br />treatment immediately.<br />If you have any further questions on the use of this product, ask your doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody<br />gets them.<br />The following side effects can happen during anaesthesia (while the injection<br />is being given to you or when you are sleepy or asleep). Your doctor<br />will be looking out for these. If they happen, your doctor will give you<br />appropriate treatment.</p><p>A doctor must be called immediately if any of the following happens:<br />Common (may affect up to 1 in 10 people):<br />&bull; Low blood pressure that might occasionally need infusion of fluids and<br />reduction of the speed of administration of propofol.<br />&bull; Slow heartbeat that might be serious in rare cases.<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; Twitching and shaking of your body, or a fit (may also happen when you<br />wake up).<br />&bull; Convulsions like in epilepsy<br />Very rare (may affect up to 1 in 10,000 people):<br />&bull; Allergic reactions up to allergic shock including swelling of the face,<br />tongue or throat, wheezing breath, skin redness and low blood pressure<br />&bull; There have been cases of unconsciousness occurring after operations. You<br />will therefore be carefully observed during the waking-up time.<br />&bull; Stopping of your heart beat.<br />&bull; Water on lungs (lung oedema) after administration of propofol<br />&bull; Inflammation of the pancreas.<br />Not known (frequency cannot be estimated from the available data):<br />&bull; There have been reports of isolated cases of severe adverse reactions<br />presenting as a combination of the following symptoms: breakdown of<br />muscle tissue, accumulation of acidic (sour) substances in the blood, abnormally<br />high blood potassium level, high blood fat levels, abnormalities<br />in the electrocardiogram (Brugada-type ECG), liver enlargement, irregular<br />heart-beat, kidney failure and heart failure. This has been called the<br />&ldquo;propofol infusion syndrome&rdquo;. Some of the affected patients eventually<br />died. These effects have only been seen in patients in intensive care,<br />mostly in patients with serious head injuries and in children with respiratory<br />tract infections who received dosages higher than recommended for<br />adults. See also section 2, &lsquo;Warnings and precautions&rsquo;.</p><p>Other side effects are:<br />Very common (affects more than 1 treated patient of 10):<br />&bull; Pain at the injection site occurring during the first injection. The pain<br />may be reduced by injecting propofol into larger veins of the forearm.<br />Injection of lidocaine (a local anaesthetic) and propofol at the same time<br />also helps to reduce the pain at the injection site.<br />Common (may affect up to 1 in 10 people):<br />&bull; Short interruption of breathing<br />&bull; Headache during the time of recovery<br />&bull; Sickness or vomiting during the time of recovery<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Blood clots in veins or inflammation of veins at the injection site<br />Very rare (may affect up to 1 in 10,000 people):<br />&bull; Loss of sexual control during the time of recovery<br />&bull; Abnormal colour of urine after longer lasting administration of propofol<br />&bull; Cases of fever after an operation<br />&bull; Redness or soreness where the injection was given.<br />&bull; Being unconscious after the operation. (When this has happened, the<br />patients have recovered without problems.)<br />&bull; Tissue damage after the medicine was accidentally injected outside of a<br />vein<br />Not known (frequency cannot be estimated from the available data):<br />&bull; Involuntary movements<br />&bull; Abnormally good mood<br />&bull; Drug abuse and drug dependence<br />&bull; Failure of the heart<br />&bull; Shallow breathing<br />&bull; Pain and/or swelling at the injection site after the medicine was accidentally<br />injected outside of a vein<br />&bull; Breakdown of muscle tissue has been reported very rarely in cases where<br />propofol has been given at greater doses than recommanded for sedation<br />in intensive care units<br />The following side effects have been seen in children in intensive care when<br />Propofol-Lipuro has been stopped suddenly.</p><p>Common (may affect up to 1 in 10 people)<br />&bull; &lsquo;Withdrawal symptoms&rsquo;. These include unusual behaviour, sweating,<br />shaking and feeling anxious.<br />&bull; Flushing of the skin.<br />&nbsp;</p><p><strong>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes<br />any possible side effects not listed in this leaflet. You can also report<br />the side effects directly via<br />The national Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax:+966-11-205-7662<br />Call NPC at +966-11-2038222<br />Exts. 2317-2356-2353-2354-2334-2340<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</strong></p><p>By providing side effects you can help provide more information on th esafety<br />of this medicine.<br />If you get any side effects, talk to your doctor or nurse. This includes any<br />possible side effects not listed in this leaflet. By reporting side effects you<br />can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label<br />and the carton after EXP. The expiry date refers to the last day of that<br />month.<br /><br />Do not store above 25&deg;C. Do not freeze.</p><p>Propofol-Lipuro 10 mg/ml must be used immediately after opening the vial<br />or ampoule.</p><p>Dilutions of Propofol-Lipuro 10 mg/ml must be used immediately after<br />preparation..</p><p>Do not use Propofol-Lipuro 10 mg/ml if two separate layers can be seen<br />after shaking the product or if it is not milky-white.</p><p>Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is propofol<br />Each millilitre of Propofol-Lipuro 10 mg/ml contains 10 mg of propofol.<br />1 ampoule with 10 ml contains 100 mg propofol.<br />1 ampoule or vial with 20 ml contains 200 mg propofol.<br />1 vial with 50 ml contains 500 mg propofol.<br />1 vial with 100 ml contains 1000 mg propofol.<br />&bull; The other ingredients are:<br />Soya-bean oil refined,<br />Medium-chain triglycerides,<br />Egg phospholipids for injection,<br />Glycerol,<br />Sodium oleate,<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                It is an emulsion for injection or infusion.
It is a milky-white oil-in water emulsion.
It comes in:
• glass ampoules of 10 millilitres, available in packs of 10 ampoules
• glass ampoules of 20 millilitres, available in packs of 5 ampoules
• glass vials of 20 millilitres, available in packs of 10 vials
• glass vials of 50 or 100 millilitres, available in packs of one or 10 vials.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>B. Braun Melsungen AG<br />Carl-Braun-Stra&szlig;e 1<br />34212 Melsungen<br />Germany<br />Postal address:<br />34209 Melsungen<br />Germany<br />Tel.: +49-5661-71-0<br />Fax: +49-5661-71-45 67</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي&nbsp;Propofol-Lipuro&nbsp;&nbsp;إلى مجموعة من الأدوية تُسمى أدوية التخدير العام. تُستخدم أدوية<br />التخدير العام في إحداث فقدان الوعي )النوم( حتى يمكن القيام بالعمليات الجراحية أو الإجراءات الأخرى. ويمكن<br />أن تُستخدم أيضًا في تهدئتك )بحيث تشعر بالنعاس ولكن لا تصبح نائمًا بشكل كامل(.<br />10 مجم/مل في صورة حقن بواسطة طبيبك. Propofol-Lipuro سيتم إعطاؤك<br />10 مجم/مل لدى البالغين والأطفال الذين يزيد عمرهم عن شهر واحد: Propofol-Lipuro يُستخدم<br />&bull; للمساعدة على أن تجعلك تنام قبل أي عملية أو إجراء آخر.<br />&bull; لإبقائك نائمًا أثناء أي عملية أو إجراء آخر.<br />&bull; لتهدئتك أثناء الإجراءات التشخيصية أو الجراحية، وذلك بمفرده أو بالتزامن مع استخدام مخدر موضعي أو مخدر<br />طرفي.<br />ويستخدم أيضا لدى الأشخاص البالغين من العمر أكثر من 16 عامًا للأغراض التالية:<br />.)ICU( &bull; تهدئتك أثناء تلقي التنفس الاصطناعي في وحدة العناية المركزة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم&nbsp;Propofol-Lipuro&nbsp;</p><p>&bull; إذا كنت مصابًا بالحساسية تجاه البروبوفول، أو الصويا، أو الفول السوداني، أو أي من مكونات هذا الدواء المذكورة في القسم (6)<br />&bull; إذا كنت تبلغ من العمر 16 عاما أو أصغر للتهدئة أثناء تلقي الرعاية في العناية المركزة.<br />10 مجم/مل وأخبر طبيبك أو أخصائي التخدير Propofol-Lipuro إذا انطبق عليك أي مما ذكر أعلاه،</p><p>فلا تتناول&nbsp;Propofol-Lipuro&nbsp;إذا انطبق عليك أي مما ذكر أعلاه,&nbsp;وأخبر طبيبك أو أخصائي التخدير.&nbsp;</p><p>تحذيرات واحتياطات<br />10 مجم/مل لدى الأطفال حديثي الولادة Propofol-Lipuro لا يوصى باستخدام<br />10 مجم/مل Propofol-Lipuro تحدث إلى طبيبك أو أخصائي التخدير أو الممرضة قبل استخدام<br />قبل أن يتم إعطاؤك هذا الدواء، أخبر طبيبك، أو أخصائي التخدير، أو الممرضة بالتالي:<br />&bull; إذا كان قد تم إخبارك مسبقًا أن لديك مستويات مرتفعة جدًا من الدهون في دمك،<br />&bull; إذا كان قد تم إخبارك مسبقًا أن جسمك يعاني من مشكلة في استخدام الدهون،<br />&bull; إذا كان جسمك قد فقد كميات كبيرة من الماء )أي تعاني من الجفاف(،<br />&bull; إذا كان حجم دمك قليل للغاية )نقص حجم الدم(،<br />&bull; إذا كنت ضعيفًا للغاية )تعاني من الوهن( أو تعاني من مشكلات في القلب أو الكلى أو الكبد،<br />&bull; إذا كنت تعاني من ارتفاع الضغط داخل الجمجمة،<br />&bull; إذا كنت تعاني من مشكلات في التنفس،<br />&bull; إذا كنت قد أصبت من قبل بنوبة أو تشنج،<br />&bull; إذا كنت تشعر منذ بعض الوقت بأنك لست على ما يرام،<br />&bull; إذا كنت مصابًا بالمرض المتقَدِّري )مرض في الميتوكوندريا(،</p><p>يرجى أن تخبر إلى طبيبك إذا كنت مصابا بأحد هذه الأمراض، أو الحالات.<br />إذا كنت تتلقى دهونا أخرى في نفس الوقت عن طريق التقطير في وريدك، فسينتبه طبيبك إلى إجمالي حصة<br />الدهون التي تتناولها يوميا،<br />سيتم إعطاؤك بروبوفول بواسطة طبيب مدرَّب في التخدير أو العناية المركزة. ستتم مراقبتك باستمرار أثناء التخدير وفي وقت الإفاقة.<br />إذا أصبت بالعلامات الخاصة بما يطلق عليه &bdquo;متلازمة تسريب البروبوفول&ldquo; )للاطلاع على قائمة مفصلة بالأعراض<br />انظر القسم 4 &bdquo;الآثار الجانبية المحتملة&ldquo;، يجب استدعاء طبيب إذا حدث ما يلي( فسيقوم طبيبك بوقف جرعة البروبوفول على الفور.<br />تشير الدراسات التي أجريت على الحيوانات الصغيرة إلى أن الاستعمال المتكرر أو المطول لأدوية التخدير العام،<br />أو الأدوية المهدئة لدى الأطفال الأفل من 3 سنوات، أو لدى النساء الحوامل أثناء الأثلوث الثالث من الحمل )الأشهر<br />الثلاثة الأخيرة( قد يكون له تأثير سلبي على نمو المخ لدى الطفل. الدلالة السريرية لهذه النتائج غير السريرية غير معروف.</p><p>يُرجى الاطلاع أيضًا على قسم &bdquo;القيادة واستخدام الآلات&ldquo; للاطلاع على الاحتياطات التي ينبغي اتخاذها بعد استخدام بروبوفول.</p><p>الأطفال والمراهقون<br />مع الأطفال حديثي الولادة. Propofol-Lipuro يوصى بعدم استخدام<br />يجب عدم استخدام هذا الدواء لدى المرضى ممن يبلغون 16 عامًا أو أقل للتهدئة في وحدة العناية المركزة<br />10 مجم/مل&ldquo;(. Propofol-Lipuro )انظر القسم &bdquo;لا تستخدم<br />10 مجم/مل Propofol-Lipuro الأدوية الأخرى و<br />أخبر طبيبك أو الصيدلي إذا كنت تتلقى حاليًا، أو تلقيت مؤخرًا، أو قد تتلقى أي أدوية أخرى.<br />هذا يتضمن الأدوية التي تشتريها دون وصفة طبية والأدوية العشبية.<br />تم استخدام بروبوفول بفعالية مع أساليب التخدير الطرفية المختلفة، والتي تؤدي إلى تنميل جزء من جسمك فقط<br />)التخدير فوق الجافية والتخدير النخاعي(.<br />بالإضافة إلى ذلك، ثبت الاستخدام الآمن عند استعمال هذا الدواء بالتزامن مع الأدوية التالية<br />&bull; الأدوية التي تتلقاها قبل الجراحة<br />&bull; الأدوية الأخرى مثل أدوية إرخاء العضلات<br />&bull; أدوية التخدير التي يمكن استنشاقها<br />&bull; مسكنات الألم<br />ومع ذلك، فقد يعطيك طبيبك جرعات أقل من بروبوفول إذا كانت هناك حاجة للتخدير العام، أو التهدئة، كتكملة<br />لأساليب التخدير الطرفية.<br />قد يرى طبيبك أن الأدوية الأخرى التي لها تأثير مثبط على الجهاز العصبي المركزي، قد تزيد من تأثيرات البروبوفول<br />حين يتم إعطاؤها بالتزامن مع البروبوفول.<br />سيتم اتخاذ إجراءات رعاية خاصة إذا كنت تتلقى مضادا حيويا يحتوي على ريفامبيسين بالتزامن مع هذا الدواء &ndash; فقد<br />تتعرض لانخفاض حاد في ضغط الدم.<br />قد يقوم طبيبك بتخفيض الجرعة إذا كنت تخضع أيضا للعلاج بفالبروات )مضاد للتشنجات(<br />10 مجم/مل مع الكحول Propofol-Lipuro<br />.Propofol-Lipiro سينصحك طبيبك بشأن تناول الكحوليات قبل وبعد استخدام<br />&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />لا تتناولي بروبوفول إذا كنتِ حاملا، إلا لو كان الأمر بالغ الضرورة.<br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو كنتِ تعتقدين أنك قد تكونين حاملًا، أو كنتِ تخططين لإنجاب طفل،<br />فاطلبي المشورة من طبيبك أو الصيدلي قبل استخدام هذا الدواء.<br />أثناء الحمل ما لم تكن هناك حاجة حتمية لذلك. فهو يعبر المشيمة وقد Propofol-Lipuro ينبغي عدم استخدام<br />يتسبب في تثبيط الوظائف الحيوية لدى حديثي الولادة.<br />إلا أنه يمكن استخدام بروبوفول أُثناء إجراء الإجهاض المحرَّض.<br />إذا كنتِ ترضعين طفلكِ رضاعة طبيعية، ينبغي أن تتوقفي عن الرضاعة وتتخلصي من لبن الثدي طوال ال 24<br />10 مجم/مل. أظهرت الدراسات التي أجريت على النساء اللاتي يرضعن رضاعة Propofol-Lipuro ساعة بعد تلقيك<br />طبيعية أن بروبوفول يُفرز في لبن الثدي بكميات صغيرة.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong><br />مجم/مل. لا تقم بالقيادة أو استخدام أي Propofol-Lipuro قد تظل تشعر بالنعاس لبعض الوقت بعد تناول 10<br />أدوات أو آلات حتى تكون متأكدًا من زوال الآثار.<br />سيقوم طبيبك بتقديم النصيحة لك<br />&bull; إذا كان ينبغي أن يصطحبك أحد الأشخاص عند مغادرتك مكان العلاج.<br />&bull; بالوقت الذي يمكنك أن تقوم فيه بالقيادة واستخدام الآلات مرة أخرى.<br />&bull; بشأن استخدام العقاقير المهدئة الأخرى )مثل المهدئات، مسكنات الألم القوية، الكحول(.<br />10 مجم/مل على الصوديوم وزيت فول الصويا Propofol-Lipuro يحتوي<br />يحتوي هذا الدواء على أقل من 1 ميلي مول من الصوديوم ) 23 مجم( لكل 100 مل، أي أنه يُعد &bdquo;خاليًا من الصوديوم&ldquo;.<br />على زيت الصويا. إذا كنت مصابًا بالحساسية تجاه الفول السوداني أو الصويا، فلا تستخدم Propofol-Lipuro يحتوي<br />هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>10 مجم/مل بواسطة أخصائيي تخدير، أو أطباء تم تدريبهم بشكل خاص في وحدة Propofol-Lipuro سيتم إعطاء<br />العناية المركزة.<br />الجرعة<br />ستختلف الجرعة التي تتناولها بناءً على عمرك، ووزن جسمك، وحالتك البدنية. سيقوم الطبيب بإعطاء الجرعة<br />الصحيحة لبدء التخدير واستمراره، أو للوصول إلى المستوى المطلوب من التهدئة من خلال مراقبة استجاباتك،<br />وعلاماتك الحيوية بدقة )النبض، ضغط الدم، التنفس، إلخ(.<br />إذا كان ذلك ضروريًا، فسيقوم الطبيب أيضًا بملاحظة حدود وقت الإعطاء.<br />10 مجم/مل عن طريق الحقن، عند استخدامه لتحريض التخدير العام، وعن Propofol-Lipuro غالبًا سيتم إعطاء<br />طريق التسريب الوريدي المستمر )الحقن بشكل أبطأ على مدار فترة زمنية أطول( عند استخدامه بغرض استمرار<br />التخدير العام. ويمكن أن يُعطى في صورة تسريب سواءً أكان مخففًا أو غير مخفف. عند استخدامه كمهدئ فغالبًا<br />سيُعطى عن طريق التسريب.<br />10 مجم/مل لمدة 7 أيام فقط بحد أقصى. Propofol-Lipuro سيتم إعطاء<br />قد تحتاج إلى عدة أدوية أخرى لإبقائك نائمًا، أو نعسانًا أو لإراحتك من الألم، أو لتجعلك تتنفس بطريقة صحية،<br />وليبقي ضغط دمك ثابتًا. سيقرر الطبيب ما هي الأدوية التي تحتاجها ومتى يجب أن تتناولها.<br />طريقة الاستعمال<br />10 مجم/مل من خلال الحقن عن طريق الحقن أو التسريب الوريدي، أي من خلال Propofol-Lipuro ستتلقى<br />إبرة أو أنبوب صغير يتم وضعه في أحد أوردتك. عادةً ما يتم ذلك من خلال ظهر يدك أو في ساعدك. وقد يستخدم<br />الطبيب أيضًا مضخة كهربائية للتحكم في سرعة إعطاء الحقن. يمكن أن يتم ذلك إذا كنت ستخضع لعملية تستغرق<br />فترة طويلة، أو إذا كنت محتجزًا داخل العناية المركزة.<br />10 مجم/مل لا يحتوي على مواد حافظة، فلن يستمر التسريب من قنينة واحدة من Propofol-Lipuro لأن<br />مجم/مل Propofol-Lipuro 10 مجم/مل لأكثر من 12 ساعة. التسريب من وعاء واحد من 10 Propofol-Lipuro<br />المخفف لن يستمر لأكثر من 6 ساعات.<br />ستتم مراقبة دورتك الدموية وتنفسك بشكل مستمر أثناء إعطائك الحقن أو التسريب.<br />10 مجم/مل أكثر مما ينبغي Propofol-Lipuro إذا تلقيت كمية من<br />من غير المرجح أن يحدث هذا لأن الجرعات التي تتلقاها يتم التحكم فيها بعناية شديدة.<br />ومع ذلك، إذا تلقيت جرعة زائدة عن طريق الخطأ، فقد يؤدي هذا إلى قصور في وظائف القلب والتنفس. في هذه<br />الحالة سيقوم طبيبك بتقديم أي علاج ضروري على الفور.<br />إذا كان لديك أي أسئلة أخرى تتعلق باستعمال هذا المنتج، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، غير أنها لا تصيب الجميع.<br />الآثار الجانبية التالية يمكن أن تحدث أثناء التخدير )أثناء إعطائك الحقن، أو بينما أنت نائم، أو تشعر بالنعاس(.<br />سيكون طبيبك محتاطًا لملاحظة هذه الآثار. وإذا حدثت، فسيقدم لك الطبيب العلاج الملائم.<br />يجب استدعاء طبيب على الفور إذا حدث أي من الأعراض التالية:<br />شائعة )قد تصيب ما يصل إلى 1 من كل 10 أشخاص(:<br />&bull; انخفاض ضغط الدم الذي قد يحتاج أحيانًا إلى تسريب السوائل، وتخفيض سرعة إعطاء بروبوفول.<br />&bull; بطء معدل ضربات القلب الذي قد يكون خطيرا في حالات نادرة.<br />نادرة )قد تصيب ما يصل إلى 1 من كل 1000 شخص(:<br />&bull; ارتعاش واهتزار جسدك، أو نوبة )قد تحدث أيضًا عندما تفيق(.<br />&bull; تشنجات تشبه الصرع<br />نادرة جدًا )قد تصيب ما يصل إلى 1 من كل 10000 شخص(:<br />&bull; تفاعلات تحسسية تصل إلى الصدمة التحسسية تتضمن تورم الوجه، أو اللسان، أو الحلق، والأزيز أثناء التنفس،<br />واحمرار الجلد، وانخفاض ضغط الدم.<br />&bull; لقد كان هناك حالات من فقدان الوعي حدثت بعد العمليات. لذلك ستتم مراقبتك بعناية خلال مرحلة الإفاقة.<br />&bull; توقف نبضات قلبك.<br />&bull; وجود ماء على رئتيك )وذمة الرئة( بعد استعمال بروبوفول<br />&bull; التهاب البنكرياس.</p><p>غير معروف )لا يمكن تقدير معدل التكرار من البيانات المتاحة(:<br />&bull; لقد وردت تقارير عن حالات منفردة أصيبت بتفاعلات ضارة شديدة تظهر في صورة مجموعة من الأعراض التالية:<br />تحلل نسيج العضلات، وتراكم المواد الحمضية )اللاذعة( في الدم، وارتفاع مستويات البوتاسيوم في الدم بصورة<br />غير طبيعية، وارتفاع مستويات الدهون في الدم، واضطرابات في مخطط كهربية القلب )اضطراب مخطط كهربية<br />القلب الذي يُعرف باسم متلازمة بروجادا(، وتضخم الكبد، وعدم انتظام ضربات القلب، والفشل الكلوي، وفشل<br />القلب. وقد سُمي هذا ب &bdquo;متلازمة تسريب البروبوفول&ldquo;. بعض ممن أصيبوا بهذه الأعراض انتهى الأمر بوفاتهم.<br />لوحظت هذه الآثار فقط في مرضى العناية المركزة، وغالبا لدى المرضى المصابين بإصابات خطرة في الرأس،<br />ولدى الأطفال الذين يعانون من عداوى القناة التنفسية، الذين تلقوا جرعات أعلى من الجرعة الموصى بها<br />للبالغين. انظر أيضًا القسم 2، &bdquo;تحذيرات واحتياطات&ldquo;.<br />الآثار الجانبية الأخرى هي:<br />:) شائعة جدًا )تصيب أكثر من مريض واحد يتم علاجه من كل 10<br />&bull; ألم في موضع الحقن يحدث أثناء إعطاء أول حقنة. يمكن تقليل الألم عن طريق حقن بروبوفول في أوردة أكبر<br />في الساعد. ويساعد أيضًا حقن ليدوكايين )مخدر موضعي( مع بروبوفول في نفس الوقت على تقليل الألم في<br />موضع الحقن.<br />شائعة )قد تصيب ما يصل إلى 1 من كل 10 أشخاص(:<br />&bull; انقطاع قصير في التنفس<br />&bull; الصداع خلال فترة الإفاقة<br />&bull; الغثيان أو التقيؤ خلال فترة الإفاقة<br />غير شائعة )قد تصيب ما يصل إلى شخص واحد من كل 100 شخص(:<br />&bull; تكون جلطات دموية في الأوردة، أو التهاب الأوردة عند موضع الحقن<br />نادرة جدًا )قد تصيب ما يصل إلى 1 من كل 10000 شخص(:<br />&bull; فقدان القدرة الجنسية خلال فترة الإفاقة<br />&bull; لون غير طبيعي للبول بعد استعمال بروبوفول لفترة طويلة<br />&bull; حالات الحمى بعد الخضوع لعملية<br />&bull; احمرار أو التهاب المكان الذي تم فيه الحقن.<br />&bull; فقدان الوعي بعد العملية. )عندما حدث هذا، تعافى المرضى دون مواجهة أي مشاكل.(<br />&bull; تلف الأنسجة، بعد حقن الدواء عن طريق الخطأ، خارج الوريد</p><p>غير معروف )لا يمكن تقدير معدل التكرار من البيانات المتاحة(:<br />&bull; حركات لا إرادية<br />&bull; حالة مزاجية جيدة بشكل غير طبيعي<br />&bull; سوء استخدام العقاقير، والاعتماد على العقاقير<br />&bull; فشل القلب<br />&bull; التنفس الضحل<br />&bull; الألم، و/أو التورم عند موضع الحقن بعد حقن الدواء خارج الوريد عن طريق الخطأ<br />&bull; لقد وردت تقارير عن حالات نادرة من تحلل نسيج العضلات عند إعطاء بروبوفول بجرعات أعلى من الموصى بها<br />للتهدئة في وحدات العناية المركزة<br />بشكل مفاجئ. Propofol-Lipuro لوحظت الآثار الجانبية التالية على الأطفال في العناية المركز عند إيقاف إعطاء<br />شائعة )قد تصيب ما يصل إلى 1 من كل 10 أشخاص(:<br />&bull; &bdquo;أعراض السحب.&ldquo; يتضمن هذا سلوكيات غير اعتيادية، والتعرق، والاهتزاز، والشعور بالقلق.<br />&bull; احمرار الجلد.<br />إذا عانيت من أي آثار جانبية، فتحدث إلى طبيبك، أو الصيدلي، أو الممرضة. يشمل هذا أي آثار جانبية محتملة غير<br />مذكورة في هذه النشرة. يمكنك أيضا أن تقوم بالإبلاغ عن الآثار الجانبية مباشرة عن طريق المركز الوطني للتيقظ<br />)NPC( والسلامة الدوائية<br />+966-11-205- رقم الفاكس: 7662<br />+966-11- اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على رقم: 2038222<br />2317-2356-2353-2354-2334- الأرقام الداخلية: 2340<br />رقم الهاتف المجاني: 8002490000<br />npc.drug@sfda.gov.sa : البريد الإلكتروني<br />www.sfda.gov.sa/npc : الموقع الإلكتروني<br />بالإبلاغ عن الآثار الجانبية يمكنك أن تساعد على توفير مزيد من المعلومات حول سلامة هذا الدواء.<br />إذا عانيت من أي آثار جانبية، فتحدث إلى طبيبك أو الممرضة. يشمل هذا أي آثار جانبية محتملة غير مذكورة في<br />هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</li><li>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق وعلى العلبة الكرتونية بعد الرمز.&ldquo;EXP&bdquo;</li><li>يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</li><li>لا تقم بتخزينها في درجة حرارة أعلى من 25 درجة مئوية. ولا تقم بتجميد الدواء.</li><li>يجب استخدام الدواء فورًا بعد فتح القنينة أو الأمبولة.</li><li>جب استخدام المحاليل المخففة&nbsp;فورًا بعد تحضيرها.&nbsp;</li><li>&nbsp;لا تستخدم الدواء إذا كان بإمكانك رؤية طبقتين منفصلتين بعد رج المنتج، أو لم يكن لونه أبيض حليبي.</li><li>لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلي كيف تتخلص من أي أدوية لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي بروبوفول<br />مجم/مل على 10 مجم من بروبوفول. Propofol-Lipuro يحتوي كل ميلي لتر من 10<br />تحتوي كل أمبولة سعة 10 مل على 100 مجم بروبوفول<br />تحتوي الأمبولة أو القنينة الواحدة سعة 20 مل على 200 مجم من بروبوفول.<br />تحتوي القنينة الواحدة سعة 50 مل على 500 مجم من بروبوفول.<br />تحتوي القنينة الواحدة سعة 100 مل على 1000 مجم من بروبوفول.<br />&bull; المكونات الأخرى هي:<br />زيت فول الصويا المكرر،<br />ثلاثي الجليسريد متوسط السلسلة،<br />الشحوم الفوسفورية بالبيض للحقن،<br />جليسيرول،<br />أوليات الصوديوم،<br />ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>هو مستحلب مخصص للحقن أو التسريب الوريدي. هو مستحلب من الزيت في الماء ولونه أبيض كلون الحليب. يأتي في أشكال العبوات التالية: &bull; أمبولات زجاجية سعة 10 ميلي لتر، متاحة في عبوات تحتوي على 10 أمبولات &bull; أمبولات زجاجية سعة 20 ميلي لتر، متاحة في عبوات تحتوي على 5 أمبولات &bull; قنينات زجاجية سعة 20 ميلي لتر، متاحة في عبوات تحتوي على 10 قنينات &bull; قنينات زجاجية سعة 50 ميلي لتر أو 100 ميلي لتر، متاحة في عبوات تحتوي على قنينة واحدة أو على 10 قنينات. قد لا تُطرح العبوات من كل الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>B. Braun Melsungen AG<br />Carl-Braun-Stra&szlig;e 1<br />34212 Melsungen<br />ألمانيا<br />العنوان البريدي:<br />34209 Melsungen<br />ألمانيا<br />+ 49-5661-71- رقم الهاتف: 0<br />+ 49-5661-71-45 رقم الفاكس:</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol-Lipuro 10 mg/ml emulsion for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol-Lipuro 10 mg/ml contains
per 1 ml /10mg Propofol
per 20 ml ampoule or vial /200mg Propofol
per 50 ml vial/ 500mg Propofol
per 100 ml vial /1000mg Propofol

Excipients with known effect:
1 ml emulsion for injection or infusion contains Soya-bean oil, refined 50 mg, Sodium 0.03 mg
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emulsion for injection or infusion White milky oil-in-water emulsion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol-Lipuro 10 mg/ml is a short-acting intravenous general anaesthetic indicated for<br />�� induction and maintenance of general anaesthesia in adults and children &gt; 1 month<br />�� sedation of ventilated patients &gt;16 years of age in the intensive care unit<br />�� sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children &gt; 1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General instructions<br />Propofol-Lipuro 10 mg/ml should be given in hospitals or adequately equipped day therapy units by physicians trained in anaesthesia or in the care of patients in intensive care. Circulatory and respira- tory functions should be constantly monitored (e.g. ECG, pulse-oxymeter) and facilities for mainte- nance of patent airways, artificial ventilation, and other resuscitation facilities should be immediately available at all times. For sedation during surgical or diagnostic procedures Propofol-Lipuro 10 mg/ml should not be given by the same person that carries out the surgical or diagnostic procedure.<br />Supplementary analgesic medicinal products are generally required in addition to Propofol-Lipuro 10 mg/ml.<br />Posology<br />Propofol-Lipuro 10 mg/ml is given intravenously. The dosage is adjusted individually according to the patient�s response.</p><p>General anaesthesia in adults<br />Induction of general anaesthesia:<br />Adults<br />For induction of anaesthesia Propofol-Lipuro 10 mg/ml should be titrated (approximately 4 ml [40 mg] every 10 seconds in an average healthy adult by bolus injection or infusion) against the patient�fs response until the clinical signs show the onset of anaesthesia. Most adult patients younger than 55 years are likely to require 1.5 to 2.5 mg/kg body weight. The total dose required can be reduced by lower rates of administration (2.5 ml/min [20.50 mg/min]).In patients over this age and in patients of ASA grades III and IV, especially those with impaired car- diac function, the dosage requirements will be less and the total dose of Propofol-Lipuro 10 mg/ml may be reduced to a minimum of 1 mg/kg body weight. In these patients lower rates of administration should be applied (approximately 2 ml, corresponding to 20 mg every 10 seconds).</p><p>Elderly<br />In older people the dose requirement for induction of anaesthesia with Propofol-Lipuro 10 mg/ml is reduced. The reduction should take into account of the physical status and age of the patient. The reduced dose should be given at a slower rate and titrated against the response.</p><p>Paediatric population<br />Propofol-Lipuro 10 mg/ml is not recommended for induction of anaesthesia in children aged less than 1 month.<br />For induction of anaesthesia in children over 1 month of age Propofol-Lipuro 10 mg/ml should be slowly titrated against the patient�fs response until the clinical signs show the onset of anaesthesia. The dosage should be adjusted according to age and/or body weight.<br />Most patients over 8 years of age require approximately 2.5 mg/kg body weight of propofol for induc- tion of anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose re- quirements may be higher (2.5 . 4 mg/kg body weight).<br />For ASA 3 and 4 patients lower doses are recommended (see also Section 4.4).</p><p>Maintenance of general anaesthesia:<br />Adults<br />Anaesthesia can be maintained by administering Propofol-Lipuro 10 mg/ml either by continuous infusion or by repeat bolus injections to prevent the clinical signs of light anaesthesia. Recovery from anaesthesia is typically rapid and it is therefore important to maintain Propofol-Lipuro 10 mg/ml administration until the end of the procedure. If a technique involving repeat bolus injections is used, increments of 25 mg (2.5 ml Propofol-Lipuro 10 mg/ml) to 50 mg (5.0 ml Propofol-Lipuro 10 mg/ml) may be given according to clinical requirements. For maintenance of anaesthesia by continuous infusion the dosage requirements usually are in the range of 4 . 12 mg/kg body weight/h.<br />Elderly<br />In elderly patients, in patients of poor general condition, in patients of ASA grades III and IV and in hypovolaemic patients the dosage may be reduced further depending on the severity of the patient�fs condition and on the performed anaesthetic technique.<br />Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.<br />Paediatric population<br />Propofol-Lipuro 10 mg/ml is not recommended for induction of anaesthesia in children aged less than 1 month.<br />Anaesthesia can be maintained in children over 1 month of age by administering Propofol-Lipuro 10 mg/ml by infusion or repeated bolus injection to maintain the depth of anaesthesia required. The required rate of administration varies considerably between patients but rates in the region of 9 . 15 mg/kg/h usually achieve satisfactory anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher.<br /><br />For ASA III and IV patients lower doses are recommended (see also section 4.4)</p><p>�� Sedation of ventilated patients in the Intensive Care Unit<br />For sedation during intensive care it is advised that propofol should be administered by continuous in- fusion. The infusion rate should be determined by the desired depth of sedation. In most patients suffi- cient sedation can be obtained with a dosage of 0.3 - 4 mg/kg/h of propofol (see also section 4.4).<br />Propofol is not indicated for sedation in intensive care of patients of 16 years of age or younger (see section 4.3).<br />Administration of propofol by Target Controlled Infusion (TCI) system is not advised for sedation in the intensive care unit.</p><p>�� Sedation for diagnostic and surgical procedures in adults<br />To provide sedation during surgical and diagnostic procedures, doses and administration rates should be adjusted according to the clinical response. Most patients will require 0.5 . 1 mg/kg body weight over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol-Lipuro 10 mg/ml infusion to the desired level of sedation. Most patients will require 1.5 .<br />4.5 mg/kg body weight/h. The infusion may be supplemented by bolus administration of 10 . 20 mg (1 . 2 ml Propofol-Lipuro 10 mg/ml) if a rapid increase of the depth of sedation is required.<br />In patients older than 55 years and in patients of ASA grades III and IV lower doses of Propofol- Lipuro 10 mg/ml may be required and the rate of administration may need to be reduced.</p><p>�� Sedation for diagnostic and surgical procedures in children over 1 month of age<br />Doses and administration rates should be adjusted according to the required depth of sedation and the clinical response. Most paediatric patients require 1 . 2 mg/kg body weight of propofol for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol-Lipuro 10 mg/ml as in- fusion to the desired level of sedation. Most patients require 1.5 . 9 mg/kg/h of propofol. The infusion may be supplemented by bolus administration of up to 1 mg/kg b.w. if a rapid increase of depth of se- dation is required.<br />In ASA III and IV patients lower doses may be required.<br />Method and duration of administration</p><p>�� Method of administration</p><p>Intravenous use<br />Propofol-Lipuro 10 mg/ml is administered intravenously by injection or continuous infusion either undiluted or diluted with 5 % w/v glucose solution or 0.9 % w/v sodium chloride solution (see also section 6.6).<br />Containers should be shaken before use.<br />Before use, the neck of the ampoule or the surface of the rubber stopper of the vial should be cleaned with medicinal alcohol (spray or swabs). After use, tapped containers must be discarded.<br />Propofol-Lipuro 10 mg/ml contains no antimicrobial preservatives and supports growth of microor- ganisms. Therefore, Propofol-Lipuro 10 mg/ml is to be drawn up aseptically into a sterile syringe or an infusion set immediately after opening the ampoule or breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both Propofol-Lipuro 10 mg/ml and the in- fusion equipment throughout the infusion period.<br />Any medicinal products or fluids added to a running Propofol-Lipuro 10 mg/ml infusion must be ad-<br />ministered close to the cannula site. If infusion sets with filters are to be used, these must be lipid permeable.<br />The contents of one ampoule or one vial of Propofol-Lipuro 10 mg/ml and any syringe containing Propofol-Lipuro 10 mg/ml are for single use in one patient.</p><p>Infusion of undiluted Propofol-Lipuro 10 mg/ml<br />When administering Propofol-Lipuro 10 mg/ml by continuous infusion, it is recommended that bu- rettes, drop counters, syringe pumps or volumetric infusion pumps, should always be used to control the infusion rates. As established for the parenteral administration of all kinds of fat emulsions, the du- ration of continuous infusion of Propofol-Lipuro 10 mg/ml from one infusion system must not exceed 12 hours. The infusion line and the reservoir of Propofol-Lipuro 10 mg/ml must be discarded and re- placed after 12 hours at the latest. Any portion of Propofol-Lipuro 10 mg/ml remaining after the end of infusion or after replacement of the infusion system must be discarded.</p><p>Infusion of diluted Propofol-Lipuro 10 mg/ml<br />For administering infusion of diluted Propofol-Lipuro 10 mg/ml, burettes, drop counters, syringe pumps, or volumetric infusion pumps should always be used to control infusion rates and to avoid the risk of accidentally uncontrolled infusion of large volumes of diluted Propofol-Lipuro 10 mg/ml.<br />The maximum dilution must not exceed 1 part of Propofol-Lipuro10 mg/ml with 4 parts of 5 % w/v glucose solution or 0.9 % w/v sodium chloride solution (minimum concentration 2 mg propofol/ml). The mixture should be prepared aseptically immediately prior to administration and must be used within 6 hours of preparation.</p><p>In order to reduce pain on initial injection, Propofol-Lipuro 10 mg/ml may be mixed with preserva- tive-free lidocaine injection 1 % (mix 20 parts of Propofol-Lipuro 10 mg/ml with up to 1 part of lido- caine injection 1 %).<br />Before giving the muscle relaxants atracurium or mivacurium subsequent to Propofol-Lipuro 10 mg/ml through the same intravenous line, it is recommended that the line be rinsed prior to administra- tion.<br />Propofol may also be used by Target Controlled Infusion. Due to the different algorithms available on the market for dosage recommendations please refer to the instructions for use leaflet of the device manufacturer.<br />This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>�� Duration of administration<br />Propofol-Lipuro 10 mg/ml can be administered for a maximum period of 7 days</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol-Lipuro 10 mg/ml is contraindicated in patients with a known hypersensitivity to propofol or to any of the excipients.
Propofol-Lipuro 10 mg/ml contains soya-bean oil and should not be used in patients who are hypersensitive to peanut or soya.
Propofol-Lipuro 10 mg/ml must not be used in patients of 16 years of age or younger for sedation for intensive care (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care of patients in Intensive Care).</p><p>Patients should be constantly monitored and facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all times. Propofol should not be administered by the person conducting the diagnostic or surgical procedure.</p><p>The abuse of and dependence on propofol, predominantly by health care professionals, has been reported. As with other general anaesthetics, the administration of propofol without airway care may result in fatal respiratory complications.</p><p>When propofol is administered for conscious sedation, for surgical and diagnostic procedures, patients should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.</p><p>As with other sedative agents, when propofol is used for sedation during operative procedures, invol- untary patient movements may occur. During procedures requiring immobility these movements may be hazardous to the operative site. An adequate period is needed prior to discharge of the patient to ensure full recovery after use of propofol. Very rarely the use of propofol may be associated with the development of a period of post- operative unconsciousness, which may be accompanied by an increase in muscle tone. This may or may not be preceded by a period of wakefulness. Although recovery is spontaneous, appropriate care of an unconscious patient should be administered.</p><p>Propofol induced impairment is not generally detectable beyond 12 hours. The effects of propofol, the procedure, concomitant medications, the age and the condition of the patient should be considered when advising patients on:<br />�h The advisability of being accompanied on leaving the place of administration<br />�h The timing of recommencement of skilled or hazardous tasks such as driving<br />�h The use of other agents that may sedate (e.g. benzodiazepines, opiates, alcohol.)</p><p>As with other intravenous anaesthetic agents, caution should be applied in patients with cardiac, respi- ratory, renal or hepatic impairment or in hypovolaemic, dehydrated or debilitated patients (see also section 4.2).</p><p>Propofol clearance is blood flow dependent, therefore, concomitant medication that reduces cardiac output will also reduce propofol clearance.</p><p>Propofol lacks vagolytic activity and has been associated with reports of bradycardia (occasionally profound) and also asystole. The intravenous administration of an anticholinergic agent before induc- tion or during maintenance of anaesthesia should be considered, especially in situations where vagal tone is likely to predominate or</p><p>when propofol is used in conjunction with other agents likely to cause bradycardia.<br />When propofol ia administered to an epileptic patient, there may be a risk of convulsion.<br />Before anaesthesia of an epileptic patient, it should be checked that the patient has received the antiepileptic treatment.</p><p>Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously.<br />It is recommended that blood lipid levels should be monitored if propofol is administered to patients thought to be at particular risk of fat overload. Administration of propofol should be adjusted appro- priately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the propofol formulation; 1.0 ml of Propofol- Lipuro 10 mg/ml contains 0.1 g of fat.<br /><br />The benefits and risks of the proposed procedure should be considered prior to proceeding with repeated or prolonged use (&gt;3 hours) of propofol in young children (&lt; 3 years) and in pregnant women as there have been reports of neurotoxicity in preclinical studies, see Section 5.3.</p><p>Paediatric population<br />The use of propofol is not recommended in newborn infants as this patient population has not been fully investigated. Pharmacokinetic data (see section 5.2) indicate that clearance is considerably re- duced in neonates and has a very high inter-individual variability. Relative overdose could occur on administering doses recommended for older children and result in severe cardiovascular depression.<br />Propofol must not be used in patients of 16 years of age or younger for sedation for intensive care as the safety and efficacy of propofol for (background) sedation in children younger than age group have not been demonstrated.</p><p>Advisory statements concerning Intensive Care Unit management</p><p>Use of propofol for ICU sedation has been associated with a constellation of metabolic disturbances and system organ failures that may result in death. Reports have been received of combinations of the following: Metabolic acidosis, Rhabdomyolysis, Hyperkalaemia, Hepatomegaly, Renal failure, Hyperlipidaemia, Cardiac arrhythmia, Brugada-type ECG (elevated ST-segment and coved T-wave) and rapidly progressive Cardiac failure usually unresponsive to inotropic supportive<br />treatment.(in some cases with fatal outcome) in adults Combinations of these events have been referred to as the Propofol infusion syndrome.</p><p>These events were mostly seen in patients with serious head injuries and children with respiratory tract infections who received dosages in excess of those advised in adults for sedation in the intensive care unit.</p><p>The following appear to be the major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents - vasoconstrictors, steroids, inotropes and/or propofol (usually following extended dosing at dose rates greater than 4mg/kg/h for more than 48 hours).</p><p>Prescribers should be alert to these events in patients with the above risk factors and immediately discontinue propofol when the above signs develop. All sedative and therapeutic agents used in the intensive care unit (ICU), including propofol, should be titrated to maintain optimal oxygen delivery and haemodynamic parameters. Patients with raised intra-cranial pressure (ICP) should be given appropriate treatment to support the cerebral perfusion pressure during these treatment modi- fications. Treating physicians are reminded if possible not to exceed the dosage of 4 mg/kg/h.</p><p>Additional precautions<br />Caution should be taken when treating patients with mitochondrial disease. These patients may be susceptible to exacerbations of their disorder when undergoing anaesthesia, surgery and ICU care. Maintenance of normothermia, provision of carbohydrates and good hydration are recommended for such patients. The early presentations of mitochondrial disease exacerbation and of the ��propofol infusion syndrome�� may be similar.</p><p>Propofol-Lipuro 10 mg/ml contains no antimicrobial preservatives and supports growth of micro- organisms.<br />When propofol is to be aspirated, it must be drawn aseptically into a sterile syringe or giving set im- mediately after opening the ampoule or breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both propofol and infusion equipment throughout the infusion period. Any infusion fluids added to the propofol line must be administered close to the cannula site.<br />If infusion sets with filters are to be used, these must be lipid-permeable.</p><p>Propofol and any syringe containing propofol are for single use in an individual patient. In accordance<br /><br />with established guidelines for other lipid emulsions, a single infusion of propofol must not exceed 12 hours. At the end of the procedure or at 12 hours, whichever is the sooner, both the reservoir of propofol and the infusion line must be discarded and replaced as appropriate.</p><p>This medicinal product contains less than 1 mmol (23 mg) sodium in 100 ml, i.e. essentially ��sodium free��.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol has been used in association with spinal and epidural anaesthesia and with commonly used premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological incompatibility has been encountered. Lower doses of propofol may be required where general anaesthesia or sedation is used as an adjunct to regional anaesthetic techniques.</p><p>The concurrent administration of other CNS depressants such as pre-medication drugs, inhalation agents, analgesic agents may add to the sedative, anaesthetic and cardiorespiratory depressant effects of propofol. Profound hypotension has been reported following anaesthetic induction with propofol in patients treated with rifampicin.</p><p>A need for lower propofol doses has been observed in patients taking valproate. When used concomitantly, a dose reduction of propofol may be considered./</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of propofol during pregnancy has not been established. Studies in animals have shown reproductive toxicity (see section 5.3).<br />Propofol should not be given to pregnant women except when absolutely necessary. Propofol crosses the placenta and can cause neonatal depression. Propofol can, however, be used during an induced abortion.</p><p>Breast-feeding<br />Studies of breast-feeding mothers showed that small quantities of propofol are excreted in human milk. Women should therefore not breastfeed for 24 hours after administration of propofol. Milk pro- duced during this period should be discarded.</p><p>Fertility<br />No data available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after use of propofol. Propofol induced impairment is not generally detectable beyond 12 hours (please see section 4.4).VB</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Induction and maintenance of anaesthesia or sedation with propofol is generally smooth with minimal evidence of excitation. The most commonly reported ADRs are pharmacologically predictable side effects of an anaesthetic/sedative agent, such as hypotension. . These effects depend on the propofol dose administered but also on the type of premedication and other concomitant medication. The nature, severity and incidence of adverse events observed in patients receiving propofol may be related to the condition of the recipients and the operative or therapeutic procedures being undertaken.</p><p><img src="data:image/png;base64,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" alt="" width="426" height="532" vspace="0" hspace="0" border="0" style="width:426px;height:532px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><img src="data:image/png;base64,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" alt="" width="412" height="399" vspace="0" hspace="0" border="0" style="width:412px;height:399px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />(1) Serious bradycardias are rare. There have been isolated reports of progression to asystole.<br />(2) Occasionally, hypotension may require use of intravenous fluids and reduction of the administration rate of propofol.<br />(3) Very rare reports of rhabdomyolysis have been received where propofol has been given at doses greater<br />than 4 mg/kg/hr for ICU sedation.<br />(4) May be minimised by using the larger veins of the forearm and antecubital fossa. With Propofol-Lipuro 10 mg/ml local pain can also be minimised by the co-administration of lidocaine.<br />(5) Combinations of these events, reported as �Propofol infusion syndrome�, may be seen in seriously ill pa- tients who often have multiple risk factors for the development of the events, see section 4.4.<br />(6) Brugada-type ECG - elevated ST-segment and coved T-wave in ECG.<br />(7) Rapidly progressive cardiac failure (in some cases with fatal outcome) in adults. The cardiac failure in such cases was usually unresponsive to inotropic supportive treatment.<br />(8) Drug abuse, predominantly by health care professionals.<br />(9) Not known as it cannot be estimated from the available clinical trial data.<br />(10) Necrosis has been reported where tissue viability has been impaired.<br />(11) Treatment is symptomatic and may include immobilisation and, if possible, elevation of affected limb, cooling, close observation, consultation of surgeon if necessary.�</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Accidental overdose is likely to cause cardiorespiratory depression.<br /><br />Treatment<br />Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression may require lowering the patient�s head and if severe, use of plasma expanders and pressor agents.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco therapeutic group: other general anaesthetics, ATC-code: N01AX10.</p><p>Mechanism of action, pharmacodynamic effect<br />After intravenous injection of Propofol-Lipuro 10 mg/ml, onset of the hypnotic effect occurs rapidly.<br />Depending on the rate of injection, the time to induction of anaesthesia is between 30 and 40 seconds. The duration of action after a single bolus administration is short due to the rapid metabolism and ex- cretion (4 � 6 minutes).</p><p>With the recommended dosage schedule, a clinically relevant accumulation of propofol after repeated bolus injection or after infusion has not been observed.</p><p>Patients recover consciousness rapidly.Bradycardia and hypotension occasionally occur during induction of anaesthesia probably due to a lack of vagolytic activity. The cardio-circulatory situation usually normalises during maintenance of anaesthesia.</p><p>The formulation of propofol in a mixed medium- and long-chain triglyceride emulsion leads to lower concentrations of free medicinal product in the aqueous phase compared to pure long-chain triglyceride emulsions. This difference may explain the reduced pain frequency and intensity observed with Propofol-Lipuro formulations in comparative clinical studies, due to the very low concentration of free propofol.</p><p>Paediatric population<br />Limited studies on the duration of propofol based anaesthesia in children indicate safety and efficacy is unchanged up to duration of 4 hours. Literature evidence of use in children documents use for pro- longed procedures without changes in safety or efficacy.w��$</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution<br />After intravenous administration about 98 % of propofol is bound to plasma protein.</p><p>After intravenous bolus administration the initial blood level of propofol declines rapidly due to rapid distribution into different compartments (��-phase). The distribution half-life has been calculated as 2 �V 4 minutes.</p><p>During elimination the decline of blood levels is slower. The elimination half-life during the ��-phase is in the range of 30 to 60 minutes. Subsequently a third deep compartment becomes apparent, repre- senting the re-distribution of propofol from weakly perfused tissue.<br />The central volume of distribution is in the range of 0.2 �V 0.79 l/kg body weight, the steady-state vol- ume of distribution in the range of 1.8 �V 5.3 l/kg body weight.</p><p>Biotransformation<br />Propofol is mainly metabolized in the liver to form glucuronides of propofol and glucuronides and sulphate conjugates of its corresponding quinol. All metabolites are inactive.</p><p>Elimination<br />Propofol is rapidly cleared from the body (total clearance approx. 2 l/min). Clearance occurs by me- tabolism, mainly in the liver, where it is blood flow dependent. Clearance is higher in children com- pared with adults. About 88 % of an administered dose is excreted in the form of metabolites in urine. Only 0.3 % is excreted unchanged in urine.</p><p>Paediatric population<br />After a single dose of 3 mg/kg intravenously, propofol clearance/kg body weight increased with age as follows: Median clearance was considerably lower in neonates &lt; 1 month old (n = 25) (20 ml/kg/min) compared to older children (n = 36, age range 4 months �V 7 years). Additionally inter-individual vari- ability was considerable in neonates (range 3.7 �V 78 ml/kg/min). Due to this limited trial data that in- dicates a large variability, no dose recommendations can be given for this age group.</p><p>Median propofol clearance in older aged children after a single 3 mg/kg bolus was 37.5 ml/min/kg (4- 24 months) (n = 8), 38.7 ml/min/kg (11�V 43 months) (n = 6), 48 mL/min/kg (1 �V 3 years)(n = 12), 28.2 ml/min/kg (4 �V 7 years)(n = 10) as compared with 23.6 ml/min/kg in adults (n = 6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no specific hazard for humans based on conventional studies on repeated dose toxicity or genotoxicity. Carcinogenicity studies have not been conducted.</p><p>Published studies in animals (including primates) at doses resulting in light to moderate anaesthesia demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in cell loss in the developing brain that can be associated with prolonged cognitive deficiencies. The clinical significance of these nonclinical findings is not known.<br />In local tolerance studies, intramuscular injection resulted in tissue damage around the injection site</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Soya-bean oil, refined,</p><p>medium-chain triglycerides,</p><p>glycerol,<br />egg phospholipids</p><p>for injection,<br />sodium oleate,</p><p>water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After first opening:
to be used immediately.
After dilution according to directions:
administration of dilution must commence immediately after preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25 C<br /><br />Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless Type I glass ampoules containing 20 ml of emulsion.</p><p>Colourless Type II glass vials sealed with bromobutyl rubber stoppers containing 20 ml, 50 ml or 100 ml of emulsion.<br />Pack sizes:<br />glass ampoules: 5 x 20 ml<br />glass vials: 10 x 20 ml, 1 x 50 ml, 10 x 50 ml, 1 x 100 ml, 10 x 100 ml</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Containers should be shaken before use.</p><p>For single use only. Any portion of contents remaining after use must be discarded, see section 4.2.</p><p>If two layers can be seen after shaking the medicinal product should not be used.</p><p>Propofol-Lipuro 10 mg/ml should only be mixed with the following products: glucose 50 mg/ml (5 % w/v) solution, sodium chloride 9 mg/ml (0.9 % w/v ) solution, and preservative-free lidocaine injection 10 mg/ml (1 %) (see section 4.2 &quot;Method and duration of administration&quot; &quot;Infusion of diluted Propofol-Lipuro 10 mg/ml�).</p><p>Co-administration of Propofol-Lipuro 10 mg/ml together with glucose 50 mg/ml (5 % w/v) solution or sodium chloride 9 mg/ml (0.9 % w/v ) solution via a Y-connector close to the injection site is possible.�O�</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                B. Braun Melsungen AG 
Carl-Braun-Str 1 
34212 Melsungen Germany
Postal address: 
34209 Melsungen Germany
Tel.: +49-5661-71-0
Fax: +49-5661-71-45 67is.Ab().t
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>